Payment overview · 2025
General Payments
$1,098.62
63 reported records · 23 companies
Healthcare provider profile · identity verified
John D Patsimas, MD
Allopathic & Osteopathic Physicians|Family Medicine · TULLAHOMA, TN · NPI 1649376849
Verified facts
What the public records show
CMS Open Payments records show John D Patsimas, MD received $1,098.62 in general payments during 2025 across 63 reported records.
Novo Nordisk Inc accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $155.22 | 14.1% | 14 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $113.40 | 10.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $84.48 | 7.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $81.30 | 7.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $77.65 | 7.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.60 | 6.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $58.90 | 5.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.59 | 5.2% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.61 | 4.7% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.06 | 4.5% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.81 | 3.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.80 | 3.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.43 | 3.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.07 | 2.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.98 | 2.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.02 | 2.0% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.96 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.39 | 1.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.37 | 1.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.20 | 1.5% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $15.76 | 1.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.54 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.48 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,098.62 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $113.40 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $111.24 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $88.42 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $77.65 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $68.60 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $68.60 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $58.90 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $51.78 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $51.61 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $49.06 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.70 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.70 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.98 | 4 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $42.81 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.43 | 2 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.52 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.72 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 144 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
144 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 411 | 114 |
| Lisinopril | Lisinopril | 330 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 292 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 227 | 57 |
| Omeprazole | Omeprazole | 227 | 70 |
| Metformin Hcl | Metformin Hcl | 215 | 66 |
| Alprazolam | Alprazolam | 180 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 48 |
| Meloxicam | Meloxicam | 155 | 49 |
| Sertraline Hcl | Sertraline Hcl | 155 | 45 |
| Gabapentin | Gabapentin | 146 | 25 |
| Eliquis | Apixaban | 144 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 41 |
| Losartan Potassium | Losartan Potassium | 137 | 35 |
| Furosemide | Furosemide | 131 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 131 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 117 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 109 | 23 |
| Montelukast Sodium | Montelukast Sodium | 109 | 29 |
| Allopurinol | Allopurinol | 105 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 97 | 71 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 30 |
| Lovastatin | Lovastatin | 89 | 27 |
| Methylprednisolone | Methylprednisolone | 88 | 66 |
| Azithromycin | Azithromycin | 85 | 70 |
| Simvastatin | Simvastatin | 84 | 25 |
| Donepezil Hcl | Donepezil Hcl | 82 | 27 |
| Gemfibrozil | Gemfibrozil | 80 | 26 |
| Sucralfate | Sucralfate | 71 | 23 |
| Trazodone Hcl | Trazodone Hcl | 70 | 17 |
| Pregabalin | Pregabalin | 69 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 18 |
| Lorazepam | Lorazepam | 66 | 11 |
| Glipizide Er | Glipizide | 64 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 25 |
| Spironolactone | Spironolactone | 61 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 16 |
| Atenolol | Atenolol | 55 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 43 |
| Tramadol Hcl | Tramadol Hcl | 53 | 22 |
| Cephalexin | Cephalexin | 51 | 32 |
| Glimepiride | Glimepiride | 49 | 15 |
| Jardiance | Empagliflozin | 49 | suppressed |
| Potassium Chloride | Potassium Chloride | 49 | 19 |
| Memantine Hcl | Memantine Hcl | 48 | 16 |
| Carvedilol | Carvedilol | 47 | 14 |
| Warfarin Sodium | Warfarin Sodium | 47 | 11 |
| Buspirone Hcl | Buspirone Hcl | 46 | 12 |
| Lactulose | Lactulose | 46 | suppressed |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Ibuprofen | Ibuprofen | 44 | 13 |
| Ozempic | Semaglutide | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | 12 |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 41 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Glipizide | Glipizide | 36 | 14 |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Prednisone | Prednisone | 32 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 12 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 20 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Bumetanide | Bumetanide | 27 | 12 |
| Fluconazole | Fluconazole | 27 | 15 |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Klor-Con 10 | Potassium Chloride | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 19 |
| Linzess | Linaclotide | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Pentoxifylline | Pentoxifylline | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 17 |
| Nystatin | Nystatin | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 14 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Acetazolamide | Acetazolamide | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Epinephrine | Epinephrine | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,098.62 · 63 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, IBSRELA, JARDIANCE, JASCAYD, JATENZO, KISUNLA, MINIMED 780G, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, RECORLEV, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, Tlando, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error